Alpine Immune Sciences, Inc. Financials

Market Capitalization $1.03 Billion as of Jan. 1, 2024

Valuations Metrics as of Jul. 5, 2025

Trailing PE	52.86
Forward PE
Price to Sales TTM	CHF22.14
Price to Book MRQ	CHF0.94
Enterprise to Revenue	22.27
Enterprise to EBITDA

Financial Reports as of Dec. 31, 2024

Financials

Fiscal Year Ends	2024-12-31
Most Recent Quarter	2024-12-31
Profit Margin	42.25%
Operating Margin	169.02%
Return on Assets TTM	0.92%
Return on Equity TTM	1.85%

Income Statement

Revenue TTM	CHF2,878,000
Revenue per Share TTM	CHF0.33
Quarterly Revenue Growth	%
Gross Profit TTM	CHF2,878,000
EBITDA	CHF0
Net Income to Common TTM	CHF1,216,000
Diluted EPS TTM	CHF0.14
Quarterly Earnings Growth YoY	%

Balance Sheet

Total Cash MRQ	CHF1,304,000
Total Cash per Share MRQ	CHF0.15
Total Debt MRQ	CHF
Total Debt to Equity MRQ	1.20
Current Ratio MRQ	1.24
Book Value per Share MRQ	CHF7.86

Cash Flow

Operating Cash Flow TTM	CHF1,316,000
Levered Free Cash Flow TTM	CHF1,874,875

ALPN Stock Info as of Jul. 5, 2025

Stock Statistics

Shares Outstanding	8,612,465
Float Shares	1,266,807
Avg 10 Volume	1,002
Avg 30 Volume	None
Shares Short	None
Short Ratio
Short % of Shares	%
% Held by Insiders	66.54%
% Held by Institutions	0.00%

Stock Price Summary

Beta	0.29
Fifty Two Week Low	CHF6.90
Fifty Two Week High	CHF7.85
Fifty Two Week Change	-3.38%
Day 50 MA	CHF7.43
Day 200 MA	CHF7.50

Dividends and Splits

Forward Annual Dividend Rate	CHF12.00
Forward Annual Dividend Yield	162.16%
Trailing Annual Dividend Rate	CHF3.00
Trailing Annual Dividend Yield	40.54%
Payout Ratio	0.00%
Dividend Date	2023-09-27
Ex Dividend Date	2023-09-25
Last Split Factor
Last Split Date	2004-09-02